[{"id":"6371f51b-3525-4eb7-98c5-08b066bcfcf3","acronym":"ONCOVIRAC","url":"https://clinicaltrials.gov/study/NCT03294486","created_at":"2021-01-29T07:15:38.091Z","updated_at":"2024-07-02T16:37:16.572Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","source_id_and_acronym":"NCT03294486 - ONCOVIRAC","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TG6002"],"overall_status":"Unknown status","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2017-11-06"}]